Congratulations to Trinomab on the Marketing Approval of Siltartoxatug! Supported by EClinCloud eCOA

Screenshot source:
NMPA official website
On February 11, Xintituo® (generic name: siltartoxatug injection)—a world-first recombinant anti-tetanus toxin monoclonal antibody drug independently developed by Zhuhai Trinomab Pharmaceutical Co., Ltd. ("Trinomab")—was formally approved for marketing by China's National Medical Products Administration (NMPA). Notably, it is the world's first recombinant fully human monoclonal antibody in the field of tetanus prevention and will fundamentally change the current landscape of tetanus prevention, offering safer and more effective protection for patients worldwide.
Xintituo® is a Category 1 new drug submitted by Trinomab. As an upgraded, next-generation "tetanus shot" for emergency tetanus prophylaxis in adults, it is administered via intramuscular injection for rapid onset to achieve emergency protection. It requires no skin test, no post-dose observation (for outpatients), and no differentiation by body weight or wound size, achieving full-course protection with a single injection and single dose.
In the clinical study of this drug, the EClinCloud eCOA solution provided strong support, helping improve the efficiency and quality of clinical trial data collection, providing more accurate and reliable evidence for drug development, and facilitating the efficient and smooth conduct of the study.
Xintituo®'s successful market launch will provide patients with a more accessible and competitive new therapy and has also set an innovative benchmark in the field of clinical research. As a key partner in technology enablement, EClinCloud will continue to provide pharmaceutical companies with reliable digital solutions to advance the intelligent transformation of clinical trials and accelerate the drug development process.


